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Group's Antimicrobial Resistance (AMR) in Neisseria gonorrhoeae (NG)
meeting was to assemble experts from academia, government, nonprofit
and industry to discuss the current state of research, gaps and challenges
in research and technology and priorities and new directions to address
the continued emergence of multidrug-resistant NG infections. Topics
discussed at the meeting, which will be the focus of this article, include
AMR NG global surveillance initiatives, the use of whole genome sequenc-
ing and bioinformatics to understand mutations associated with AMR,mech-
anisms of AMR, and novel antibiotics, vaccines and other methods to treat
AMR NG. Key points highlighted during the meeting include: (i) US and
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Antimicrobial resistance (AMR) in Neisseria gonorrhoeae(NG) continues to be a serious threat to global public health.
Although the use of dual antimicrobial therapy is highly effective,
increasing reports of NG infections with cephalosporin- and
azithromycin (AZI)-reduced susceptibility raise serious concerns
regarding the durability of current treatment recommendations.1
Although nearly 400,000 NG cases were reported in 2015, the
United States Centers for Disease Control and Prevention (CDC)
estimates about 820,000 total infections occur annually due to
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Antimicrobial Resistance in N. gonorrhoeaeAMR in NG continues to be a concern both in the United States
and globally, current nucleic acid-based amplification testingmethods
cannot measure antimicrobial susceptibility. Therefore, enhanced
molecular diagnostics that distinguish among NG infections with
antimicrobial resistance versus reduced susceptibility versus sus-
ceptibility are needed to help guide antibiotic treatment. The de-
velopment and use of new bioinformatics tools, in conjunction
with new technologies like whole genome sequencing (WGS)
methods to identify AMR NG-associated mutations may resolve
this issue at a global level. Understanding the mechanisms of
AMR inNGmay also help guide the development of new treatment
and preventative modalities. The STI Treatment and Research (STAR)
Sexually Transmitted Infection Clinical Trial Group (STI-CTG) held a
programmatic meeting in Silver Spring, Maryland on April 13, 2017,
titled: “Antimicrobial Resistance (AMR) in Neisseria gonorrhoeae
(NG)”. Experts from academia, government, nonprofit, and industry
reviewed the current state of research, gaps and challenges in research
and technology and future research and public health directions.
SURVEILLANCE PROGRAMS TO
UNDERSTAND AMR
The Sexually Transmitted Disease
Surveillance Network
To complement routine notification data, CDC established
the sexually transmitted disease (STD) Surveillance Network (SSuN)
in 2005. In select jurisdictions, laboratory test results are collected
from STD clinic attendees along with epidemiological data from a
random sample of persons with gonorrhea.3 Data are representa-
tive of NG testing of the rectum, urethra, cervix, and pharynx. In
some SSuN jurisdictions, more than 50% of reported gonorrhea cases
occurred among men who have sex with men (MSM) in 2015.4 In
other jurisdictions, cases in women and heterosexual men were more
common, suggesting epidemic differences that may require different
prevention and control approaches. In STD clinics participating in
SSuN, the NG positivity rate among MSM tested for gonorrhea
was over 5% and was elevated among HIV-infected MSM (eg, ~17%
of HIV-infected MSM tested had rectal gonorrhea.
Gonococcal Isolate Surveillance Project
Established in 1986 to monitor N. gonorrhoeae antimicro-
bial susceptibility and inform treatment guidelines, Gonococcal
Isolate Surveillance Project (GISP) is a collaboration between
the CDC, clinical sites, and regional laboratories.5 Urethral spec-
imens for culture and antimicrobial susceptibility testing are sys-
tematically collected from consecutive men with urethritis each
month at participating STD clinics according to a standardized
protocol; limited epidemiological data are locally abstracted
from medical records and later merged, by CDC, with antimicro-
bial susceptibility data. Gonococcal Isolate Surveillance Project
is designed for long-term surveillance of susceptibility trends;
data are not available in a timely manner to inform clinical man-
agement and public health response. Although GISP is aimed at
surveillance ofNG in men, the Enhanced GISP (eGISP) was later
created (2015) to strengthen surveillance of gonorrhea susceptibil-
ity and increase state and local capacity to detect and monitor NG
in women and from extragenital sites.
During 2006 to 2016, the proportion of GISP isolates with
reduced susceptibility (minimum inhibitory concentration [MIC],
≥0.125 μg/mL) to ceftriaxone) remained low (less than 0.5%).4,6
The proportion of isolates with reduced AZI susceptibility (MIC
≥2.0 μg/mL) increased from 0.6% in 2013 to 3.6% in 2016.5,6 Re-
cently, of particular concern, there were 4 GISP isolates collected in
Hawaii that had elevated MICs to both AZI (MICs, ≥16.0 μg/mL)Sexually Transmitted Diseases • Volume 46, Number 3, March 201and ceftriaxone (MICs, 0.125 μg/mL).7 Isolates collected through
GISP continue to show reduced susceptibility to antimicrobials no
longer recommended as first-line regimens; preliminary data for
2016 indicate that approximately 40% isolates had some resistance
to penicillin, tetracycline, and ciprofloxacin.
Based on the approximately 820,000 gonococcal infections
that occur each year in the United States, it was predicted that in
2011 about 246,000 infections either were resistant or had decreased
susceptibility to at least 1 antibiotic; 11,480 had reduced suscepti-
bility to cefixime (MIC, ≥0.25 μg/mL), 2460 reduced susceptibil-
ity to AZI (MIC ≥2.0 μg/mL), and 3280 reduced susceptibility to
ceftriaxone.8NG isolates with decreased susceptibility to cephalo-
sporins are often resistant to other classes of antibiotics as well.9–11
Although those susceptibility trends are concerning, it is impor-
tant to note that there have been no clinical treatment failures in
the United States with the current recommended therapy of 250-mg
ceftriaxone and 1-g AZI.
International Gonococcal Antimicrobial
Surveillance Program
To support international surveillance of gonococcal resis-
tance, the World Health Organization (WHO) founded Gonococcal
Antimicrobial Surveillance Program (GASP) in 1990.12 Gonococ-
cal Antimicrobial Surveillance Program currently has participating
countries in Africa, the Americas, the Eastern Mediterranean,
Europe, South East Asia, and Western Pacific. Different countries
have different approaches to AMR in NG.
From 2009 to 2014, the total number countries reporting to
GASP increased from 56 to 77, but there was considerable variation
between WHO regions reporting. Of the 77 countries reporting to
GASP, 66% reported isolates with any resistance/decreased suscep-
tibility ofNG to cephalosporins (cefixime or ceftriaxone), 81%with
any resistance/decreased susceptibility ofNG to AZI, and 97%with
any resistance/decreased susceptibility of NG to ciprofloxacin, for
at least 1 year from 2009 to 2014.13 Notably, there are large gaps in
data on AMR NG in Africa, Central America (extending up to
Mexico), and the Middle East with adjacent countries in Asia.
Currently, differences in the US and European guidelines for
MIC interpretation create challenges to combining disparate
country reports. Hence, as countries continue to develop ro-
bust surveillance programs and report MIC values, strategies
to combine and compare such data need to be further examined
and standardized.
Multidrug resistant (MDR) and extensively drug-resistant
(XDR) forms of NG have been identified globally, including iso-
lates from Japan,10,14–17 Hawaii,7,14,18 and England.19 The WHO
defines MDR-NG as isolates with reduced susceptibility or resis-
tance to either extended spectrum cephalosporins (ESC) or specti-
nomycin (ie, category I antibiotics), plus 2 or more of macrolides,
fluoroquinolones, penicillins, tetracycline, aminoglycosides, and
carbapenems (ie, category II antibiotics).20 XDR-NG are defined
as isolates with decreased susceptibility or resistance to category
I antibiotics and 3 or more category II antibiotics.20 Resistance
or reduced susceptibility to cephalosporins (ie, ceftriaxone) due
to the emergence of strains with mosaic penA alleles has been
noted in the aforementioned countries. Reduced susceptibility to
macrolides, such as AZI, has also been noted.20–24
Questions persist about how to either implement or en-
hance surveillance, especially in low- and middle-income coun-
tries, how best to report AMR in NG, what the cost/benefit is for
validating treatment failures in low- and middle-income countries,
whether older antibiotics can be used againwith newmolecular di-
agnostics to predict susceptibility and how to validate various
treatment guidelines from around the world. Treatment guidelines9 e19
Cristillo et al.forNGmust also be updated based on in-country surveillance data
because many countries continue to use ciprofloxacin as a rec-
ommended first-line therapy.22 One success of the GASP pro-
gram includes updated treatment guidelines for NG in countries,
such as Argentina, Chile, Bolivia, Colombia, Cuba, Uruguay,
and Venezuela.
THE RECENT PUBLIC HEALTH RESPONSE
US National Strategy for Combating
Antimicrobial-resistant Bacteria
The US National Strategy for Combating Antibiotic-
Resistant Bacteria, released in September of 2014, put forth 5
overarching goals: slowing the development of resistant bacteria
and preventing spread of resistant infections; strengthening
surveillance; advancing the development and use of rapid
and innovative diagnostics; accelerating of research and de-
velopment for new antibiotics, therapeutics, and vaccines;
and improving international collaboration.8 Reflecting the
designation of NG as 1 of 3 urgent antibiotic resistance threats,25
the National Strategy included a national target of maintain-
ing the prevalence of ceftriaxone-reduced susceptibleNG at less
than 2% through 2020 and beyond. The National Action Plan, re-
leased in March 2015, outlined a roadmap for implementing the
National Strategy.
In fiscal year 2017, congress appropriated $167 million to
CDC to support implementation of the National Strategy
through CDC's Antibiotic Resistance Solutions Initiative. Al-
though the initiative is broad-based, multiple activities focusing
on NG are included, selected activities are described below. To
strengthen surveillance, the Antibiotic Resistance Laboratory
Network was created. Seven state public health laboratories
serve as regional laboratories to conduct AMR testing of multi-
ple pathogens and specialized testing of clinical specimens.
Four of the laboratories conduct agar dilution testing of NG
for GISP and other enhanced surveillance platforms. Integration
of WGS of NG is planned.
Using Antibiotic Resistance Solutions Initiative funding,
CDC also implemented the Strengthening US Response to Resis-
tant Gonorrhea (SURRG), a collaboration between CDC and
participating jurisdictions to establish local capacity to rapidly
detect and respond to AMR in selected local jurisdictions.25 Ju-
risdictions participating in SURRG collect specimens for NG
culture in STD clinics and other health care settings conduct
rapid susceptibility testing on all isolates, interview patients in-
fected with strains with reduced antimicrobial susceptibility
and their recent contacts, and expand data collection to facilitate
epidemiological and network analyses. The Antibiotic Resistance
Solutions Initiative funding is also strengthening surveillance of
NG isolates for drug susceptibility patterns in GISP and monitor-
ing of trends of gonorrhea in SSuN.
World Health Organization
In response to the increasing threat of AMR, the World
Health Assembly adopted a global action plan on antimicrobial
resistance in May of 2015.26 The WHO's 5 objectives are: (i) to
improve awareness and understanding of antimicrobial resis-
tance through effective communication, education, and training;
(ii) to strengthen the knowledge and evidence base through sur-
veillance and research; (iii) to reduce the incidence of infection
through effective sanitation, hygiene, and infection prevention
measures; (iv) to optimize the use of antimicrobial medicines
in human and animal health; (iv) to develop the economic case
for sustainable investment that takes account of the needs of alle20 Sexuacountries; and (v) to increase investment in new medicines,
diagnostic tools, vaccines, and other interventions. This ac-
tion plan emphasizes the need for a coordinated approach
leveraging international stakeholders from different disciplines
and sectors.
SURVEILLANCE NEEDS, CHALLENGES, AND
NOVEL TECHNOLOGIES
Surveillance Needs and Challenges
From 2000 to 2010, global antibiotic usage increased by
36% and use of cephalosporins doubled,27 particularly in China
and India. Such increases in antibiotic use likely drive the selective
pressure for AMR. Although global surveillance efforts (eg, GISP/
GASP) strive to detect AMR in NG isolates, one must consider
whether those data are being collected with sufficient timeliness
to mitigate the risks. Through current surveillance programs, there
is a lag in identifying AMR NG for clinical decision making,
thereby potentially enabling continued transmission of AMR
strains. The process is limited by the constraints of current methods
and technologies in growing NG isolates, identifying AMR and its
mechanisms, and identifying isolates implicated in AMR outbreaks
through phenotypic characterization. Greater use of molecular tools
for timely and accurate detection of AMR as are applied on other
fields of infectious disease surveillance, including PCR and DNA
sequencing, is urgently needed.
Cases of ceftriaxone-reduced susceptible NG have been
found in pharyngeal specimens.21,22 Pharyngeal gonorrhea poses
multiple challenges due to its asymptomatic nature, ease of trans-
mission and difficulty of treatment. The pharynx may also serve as
anNG reservoir and incubator of reduced susceptibility because of
the frequent presence of commensal nonpathogenicNeisseria spe-
cies. Given that Neisseria species are known for DNA uptake and
exchange, it is likely that the horizontal transfer of genetic mate-
rial, including antibiotic resistance genes, in the pharynx leads to
AMR NG infections
In many regions globally, antibiotics are readily available
without a prescription, and those regions are historically known
for high levels of antibiotic resistance and have groups of people
with high rates of oropharyngeal STIs. Given that environment,
the NIH-funded (Fogarty Center) ICON Study in northern
Vietnam, enrolled MSM to address the frequency of antibiotic
use and any association with antibiotic-resistant or -susceptible
pathogenic and nonpathogenic Neisseria.28 Preliminary results
of the ICON Study found 62% of current participants reported an-
tibiotic usage in the prior 6 months, often without a prescription
and some stopped antibiotic usage as soon as symptoms abated.
Nonpathogenic Neisseria were found in 38 (100%) of 38 clinical
pharyngeal specimens, with some samples growing up to 4 dif-
ferent Neisseria species, including N. gonorrhoeae and N.
meningitidis. Next steps of the ICON Study include determin-
ing whether different Neisseria species have different capacities
for acquiring resistance, determining the prevalence of similar
genetic components in different resistant strains, and whether
Neisseria commensals can be used in surveillance to predict
tends in NG AMR.
Novel Technologies
Advances in genomics might help address AMR through
informing the development of molecular diagnostics, identifying
outbreaks, advancing the understanding of disease transmission,
and through epidemiological/evolutionary inference to guide anti-
biotic selection. Important AMR-related questions that genomics
can help address include the following: (i) How much resistancelly Transmitted Diseases • Volume 46, Number 3, March 2019
Antimicrobial Resistance in N. gonorrhoeaeis due to clonal spread and de novo emergence? (ii) Towhat extent
do known genetic resistance mechanisms explain observed pheno-
type resistance? (iii) How can the scientific community identify
novel mechanisms of resistance?
Reports have shown that increased MICs to extended-
spectrum cephalosporins (cefiximeMIC,≥0.25 μg/mL; ceftriaxone
MIC, ≥0.125 μg/mL) in the United States is predominantly associ-
ated with the mosaic penAXXXIVallele with or without additional
specific point mutations in penA.29–32 Quinolone-resistant NG has
widely spread through predominantly spread of mutations in gyrA
and parC (gyrA-S91F/I, gyrA-D95G, parC-S88P). Reduced AZI
susceptibility has arisen through multiple mechanisms, with the
most common in the United States being 23S rRNA mutations
(C2611T, and A2059G) and mosaic mtr mutations in the mtrR lo-
cus33,34 However, about a third of reduced AZI susceptibility
(MIC≥2 μg/mL) is not clearly explained by 23S rRNAmutations,
by a mosaic mtr locus, by a single basepair deletion in the mtrR
promoter or generation of a new promoter for transcription of
mtrCDE.34 Those findings indicate the utility of WGS in develop-
ing nucleotide-basedmolecular diagnostics. However, several lim-
itations are worth noting. First, not all phenotypic resistance is
explained by known mechanisms of resistance. Further, the fre-
quency with which novel mechanisms of resistance arise, mixed
strain infections occur or how to best screen for such mechanisms,
or determine the clinical impact of mixed infections is unclear.
Genomic epidemiology can help understand patterns of
spread of gonococcal strains and identify local transmission and
outbreaks. Examples include tracking the transmission of resistant
lineages across geographic and demographic boundaries,33–36 and
reconstructing local transmission networks.35,36
Development of point-of-care (POC) diagnostics to iden-
tify drug susceptibility profiles has the potential to impact overall
levels of AMR and, as 60% of gonococcal isolates in the United
States are pan-susceptible, permit reintroduction of older antibi-
otics into treatment regimens.37–42 Although a rapid test for sus-
ceptibility is expected to aid in reducing the overall burden of
AMR as compared with one that does not detect susceptibility,43
questions remain about how best to deploy these strategies.
MECHANISMS OF ANTIMICROBIAL RESISTANCE
(AMR) IN NG, AND NOVEL ANTIBIOTICS AND
VACCINES TO TREAT AMR NG
Mechanisms of β-lactam Antibiotic Resistance
in NG
There are 2 genetic sources of antibiotic resistance in NG:
plasmid-mediated and chromosomally mediated. In plasmid-
mediated resistance, β-lactam antibiotic resistance occurs due to
the expression of an antibiotic modifying protein (eg, TEM-1–
like β-lactamase for penicillin and amino-penicillin (eg, amoxicil-
lin) resistance [PenR]) or a ribosome-protected protein (TetM
ribosomal-binding protein that confers tetracycline resistance).
β-lactamase does not hydrolyze cephalosporins, so it does not
contribute to cephalosporin resistance. However, 1 amino acid
change in the bla gene could convert it to produce extended-
spectrum β-lactamase.44 In chromosomal-mediated resistance,
antibiotic resistance occurs due to de novo spontaneous mutations
or due to the acquisition of chromosomal mutations via homolo-
gous recombination commonly thought to occur from Neisseria
commensal species. In stepwise resistance, each step is a relatively
small increase in resistance, but whenmultiplied overall, it leads to
a large increase in the MIC of a given antimicrobial.
The main difference between PenR NG strains and
cephalosporin-resistant (CephR)/cephalosporin intermediate-resistantSexually Transmitted Diseases • Volume 46, Number 3, March 201strains (CephI) is due to the type of mosaic penA allele arising from
interspecies recombination.1 It appears that the origin and rapid
emergence of CephI strains was due to a single transformation
event of a mosaic penA allele into existing CephS/PenR strains,
which to this day persist even though penicillin has not been used
for NG treatment in decades.45
In addition to the penA allele, the mtrR and penB determi-
nants contribute additional resistance to β-lactam antibiotics and
provide a general permeability barrier for antibiotics.46 The mtrR
determinant, caused by mutations either in the promoter region
or coding sequence, increases transcription of the divergently tran-
scribed mtrCDE operon that encodes the MtrC-MtrD-MtrE efflux
pump.47–49 The increased expression of the pump causes in-
creased efflux of antibiotics from the cytoplasm and periplasm
of NG. The mutated penB may produce altered forms of the
PorB1B porin, the major porin of NG,
50,51 resulting in a decrease
in the influx of antimicrobials through the porin channels. It is in-
teresting that the increase in resistance conferred by penB requires
the presence of an mtrR mutation.52Novel Therapeutic and Vaccine Approaches
Novel, nontraditional therapeutic, and vaccine approaches
to combat MDR NG infection are currently being investigated.
Therapeutic approaches include sialic acid analogs (eg, chemical
therapies),53–55 FH/Fc fusion molecules54–56 andmonoclonal anti-
bodies (eg, immunotherapeutic molecules). Vaccine approaches
include widely expressed antigens that are immunogenic (eg,
common lipooligosaccharide epitopes represented by peptide
mimics)57–59 and the use of vaccines developed for otherNeisseria
species that may cross-protect against NG infections
Nongonococcal sialic acids can be used to disrupt the
natural protection on most gonococcal organisms. More specif-
ically, endogenous, host mammalian sialic acids are taken up by
gonococci in vivo and result in protection of the organism from
complement-mediated killing whereas nonhost sialic acids, de-
rived from alternative sources, do not possess this protective
function (complement resistance). With respect to mechanism
of action, when alternative sialic acids are administered locally
to infected mice, they replace host sialic acid, can be taken up
preferentially by gonococci, and hasten clearance of bacteria
by removing resistance to complement-mediated killing.53–55
Natural and synthetic sialic acids can be mined for candidates
that are optimal in eliminating complement resistance and hasten-
ing clearance of infecting bacteria.
A fusion protein has been engineered that on the one hand
binds to a complement regulator binding site, present on all gono-
cocci, called factor H, and, on the other hand, possesses an Fc do-
main that engages complement and kills the organism; thereby,
enhancing clearance in the animal model. The FH portion has
been altered so as not to bind to human cells thereby avoiding tox-
icity. The FH/Fc fusion protein constructs have been shown to
bind to 12 of 15 different gonococcal isolates, kill 10 of 15 of these
in vitro and hasten clearance of 3 different isolates infecting the
animal model.54–56 Production of FH/Fc, a fully humanized im-
munotherapeutic, is being scaled up in tobacco plants and config-
ured for use parenterally and in intravaginal release devices.
Another immunotherapeutic molecule being developed for
gonorrhea treatment is the chimeric (mouse/human) 2C7 antibody.
The 2C7 antibody has been tested, intravaginally and parenterally,
in the mouse animal model.57 The 2C7 antibody is being fully hu-
manized and like FH/Fc, production is being scaled up in tobacco
plants and configured for parenteral and intravaginal administra-
tion. Because 2C7 antibody and FH/Fc target different sites on
the organism, combining their use may be additive.9 e21
Cristillo et al.The 2C7 epitope, against which the 2C7 antibody was de-
veloped, forms the basis for a novel gonococcal vaccine.5,57,58,60
The 2C7 epitope is displayed by greater than 95% of clinical iso-
lates; antibodies against the 2C7 epitope are elicited uniformly by
women with infection.53,57,61 A 2C7 peptide mimic vaccine was
constructed by screening of randomly generated peptides (using
a peptide library consisting of >1012 peptides) and identifying pep-
tide(s) recognized by 2C7 monoclonal antibody.47 A multiantigenic
peptide (MAP; octomeric/tetrameric) was fashioned that elicited
antibodies directed against the nominal (2C7) epitope, pos-
sessed complement-dependent killing against all gonococcal
isolates tested and hastened clearance of infection in vacci-
nated animals.60 Stabilization and scale-up of homogenous
peptide (>95% pure) has already been accomplished and cur-
rent work is aimed at optimizing responses to the peptide
mimic vaccine with human-approved adjuvants. Although me-
ningococcal group B outer membrane vesicle vaccines have
been shown to be immunogenic and efficacious against homol-
ogous strains, more recently they have also been found to pro-
tect partially against NG infection. A retrospective case-control
study of patients seen in New Zealand sexual health clinics
revealed that exposure to the outer membrane vesicle meningo-
coccal B vaccine was associated with about 30% reduction in
gonorrhea diagnoses.62
Although those novel therapeutic and preventive ap-
proaches provide hope in curtailing gonococcal infections, they
will require more research and development to deliver an ap-
proved, affordable treatment for AMR NG that can be brought to
the clinic. Meanwhile, there are few novel, more traditional antibi-
otic approaches that are in development.
Novel Therapeutic for Uncomplicated NG:
Zoliflodacin/ETX0914
The standard CDC and WHO treatment recommendation
for gonorrhea requires a minimal efficacy of greater than 95% at
any mucosal site (cervix, urine, rectum, pharynx).11 An optimal
treatment would be effective against resistant isolates for both uro-
genital and extragenital infection and would be well tolerated.63
While a single-dose therapy would be ideal, single-dose therapy
versus multidose therapy is less a priority than a safe and well-
tolerated antimicrobial regimen with efficacy across resistant iso-
lates and all anatomic sites.
Zoliflodacin (Entasis Therapeutics) was developed for the
treatment of uncomplicated gonorrhea and is the first drug in a
novel class of topoisomerase inhibitors.63 Zoliflodacin has shown
potent in vitro activity against 100 gonococcal isolates and shows
a lack of cross-resistance to other antibiotic classes.64,65 Because
itsmechanismof action is distinct from fluoroquinolones, it is hypoth-
esized that zoliflodacin will be effective in treating fluoroquinolone-
resistant infections. In phase 1 studies, a single dose of zoliflodacin
was well tolerated in healthy adult males, and all adverse events
were mild/nonserious. No adverse events lead to study discontin-
uation (ClinicalTrials.gov NCT01929629).
A National Institute of Allergy and Infectious Diseases
sponsored, Phase 2 study (Clinicaltrials.gov NCT02257918) of
zoliflodacin was conducted to assess safety and microbiological
cure among 180 subjects with gonorrhea. Of the 180 subjects enrolled,
131 were analyzed as microbiological-intent-to-treat evaluable
subjects.66 The number of participants with microbiological cure
at urethral or cervical sites in the 2000-mg zoliflodacin, 3000-mg
zoliflodacin, and the 500-mg intramuscular ceftriaxone group were
55 of 57, 54 of 56, and 28 of 28, respectively.66 Among 15 patients
across the 3 groups with rectal infections, all were cured.66 The
number of patients with microbiological cure at pharyngeal sitee22 Sexuawas slightly higher in the patients treated with intramuscular ceftri-
axone (4 of 4) compared with the 3000 mg zoliflodacin group (9 of
11).66 Overall, zoliflodacin was well tolerated. Phase 3 studies of
zoliflodacin are currently being planned with support from the
Global Antibiotic Research Development Program.
Solithromycin
Solithromycin (Cempra, Inc.) is a 4th-generation macrolide
and the first fluoroketolide. It exhibits in vitro activity against a number
of urogenital pathogens includingNG,67,68Chlamydia trachomatis,69
Mycoplasma spp.,70 and Ureaplasma spp.71 Solithromycin was
tested in a phase 2 urethritis study to assess the eradication of uro-
genital NG (Clinicaltrials.gov NCT01591447) and in a phase 3
study to assess its noninferiority versus intramuscular ceftriaxone
plus oral AZI (Clinicaltrials.gov NCT02210325). The phase 2
study enrolled 59 subjects, and found 100% eradication across
all urogenital, pharyngeal, and rectal sites. Solithromycin was as-
sociated with gastrointestinal-related adverse events.72 A follow-
up phase 3 study (Clinicaltrials.gov NCT02210325) (N = 262)
compared solithromycin alone versus standard of care (500 mg in-
tramuscular ceftriaxone [CTX] plus 1 g oral AZI). In the intent-
to-treat analysis Solithromycin was not noninferior to the standard
of care (80.5% vs 84.5% cure, respectively).73 In the microbiolog-
ically evaluable population (ie, patients with a positive baseline
culture who returned for evaluation at the test of cure visit), treat-
ment success was 91.3% (95 of 104) for solithromycin recipients,
versus 100% (107 of 107) for CTX/AZI patients. Among the 9
solithromycin patients with a positive TOC culture result, there
was no correlation between outcome and solithromycin MIC
(range, 0.004–0.25 μg/mL); all baseline isolates were susceptible
to solithromycin using CDC criteria for AZI (MIC <2.0 μg/
mL).73 Emergence of solithromycin resistance in TOC isolates
was not observed. Genotyping of pretreatment and posttreatment
isolates did not demonstrate reinfection with novel strains. Given
the absence of baseline or acquired solithromycin resistance and
the absence of evidence of reinfection with a novel strain, the in-
vestigators surmised that the most likely cause of treatment fail-
ure was pharmacokinetic-related, with presumed insufficient
duration of drug exposure at the site of infection. It is hypothe-
sized that solithromycin dose adjustment (for instance, a 2-dose
strategy, over 24 hours) and combination treatment strategy with a
second antibiotic would result in desired treatment success rates. Al-
though other novel therapeutics for NG are currently being investi-
gated, including the triazaacenaphthylene antibacterial agent,
gepotidacin, these were not discussed at the programmatic meeting.OTHER MEANS TO TREAT
GONOCOCCAL INFECTION
Crippling Selective Gene Expression
Understanding themechanisms of AMR inNG can assist in
the design of newer antimicrobials and vaccines and provide in-
sights as to the development of compensatory mutations that re-
verse fitness defects yet maintain resistance. The MtrCDE drug
efflux contributes significantly to such resistance and tran-
scriptional control systems modulate levels of efflux pump
gene expressions and, as a consequence, levels of antibiotic
resistance.70–72 Mutations that increase efflux pump gene ex-
pression can adversely impact clinical efficacy of antibiotics.
Finally, dampening efflux pump gene expression might allow
for return of an old antibiotic (eg, penicillin) or allow for contin-
ued use of current antibiotics.lly Transmitted Diseases • Volume 46, Number 3, March 2019
Antimicrobial Resistance in N. gonorrhoeaeStrategy to Alter Bacterial Membranes—Lipid
A Enzymes
Lipid A is a component of bacterial outer membranes and is
essential for cell viability of nearly all Gram-negative bacteria.
Current investigations are aimed at evaluating whether small mol-
ecule inhibitors (eg, TU-514, CHIR-090, LPC-067) of LpxC, an
essential gene for NG, can be used to target NG infections. LpxC
Inhibitors (eg, LPC-169, LPC-174, LPC-201, LPC-211) have
been shown to overcome existing antibiotic resistance (unpub-
lished data). The investigators also looked at the efficacy of
LPC-211 in mouse models against a specific ceftriaxone-
resistant strain of NG. Although the investigators have found such
inhibitors to work well to treat NG, improvements are still needed
to file an IND application.NEXT STEPS: RESEARCHAND TECHNOLOGYGAPS
AND CHALLENGES
AMR NG Research Gaps and Challenges
In 2016, 7 patients in Hawaii were found to be infected with
strains demonstrating high-level AZI resistance (MICs, ≥16.0 μg/
mL) and elevated MICs to ceftriaxone (MICs, 0.125 μg/mL).7,18
Although those are rare, the chances of combined AZI and
ceftriaxone-reduced susceptibility are growing. A recent report
from China found about 3% of NG isolates with dual ceftriaxone
decreased susceptibility and AZI resistance.1 Molecular studies
have found that there is considerable variability in the mutations
associated with AZI-reduced susceptibility.32,74 An important
question to consider is how the scientific community can best
monitor reduced susceptibility to AZI in regions across the
globe. One strategy may be to increase AMR surveillance pro-
grams, like GISP/GASP, globally and expand the collection of
nonurogenital specimens.14,75
Previously, gonorrhea was treated using antimicrobial
monotherapy; specific antimicrobials were recommended based
on clinical trial results and subsequent antimicrobial susceptibility
trends. The use of dual therapy potentially introduces more com-
plexity into decisions about treatment recommendations. The
value of dual therapy to prevent AMR is only a theoretical argu-
ment at present; investigations of whether using 2 or more antibi-
otics at one time slows the development of resistance to either drug
would advance the field. To that end, murine modeling studies
may play an important role in addressing such questions in addi-
tion to understanding host-microbe interactions. Creating antimi-
crobial susceptibility testing matrices that include different doses
for each drug may help to determine if the combination of drugs
are synergistic or antagonistic and may help to address the afore-
mentioned question of resistance. Although several synergy
studies of drugs against NG have been published, little to no an-
tagonism or synergy has been noted.76–78 As new antimicrobial
agents, such as those discussed previously, and diagnostics be-
come commercially available in coming years, questions about
how to select the most effective drug combinations, weighing
both clinical efficacy and impact on resistance, should be ad-
dressed with additional synergy studies.
Syndromic Management and AMR NG
Syndromic management continues to be the principal ap-
proach for STI treatment in low- to middle-income countries be-
cause of its simplicity and affordability.36–39,79–81 Syndromic
management is based on the identification of clinical symptoms
(or signs) with resultant indications for treatment rather than mak-
ing an etiological diagnosis using laboratory methods. AlthoughSexually Transmitted Diseases • Volume 46, Number 3, March 201inexpensive and fast, the shortcomings of syndromic management
include a lack of specificity and substantial overuse of antibiotics.
Syndromic management may greatly contribute to AMR in NG.
Another problem with syndromic management is that it does not
address those with asymptomatic infections and is therefore un-
likely to impact the burden of infection. Implementing rapid
POC detection of NG as a first step in the diagnosis of gonorrhea
and potentially even more valuable the POC detection of NG with
specific antimicrobial susceptibility could profoundly impact and
slow the emergence of AMR in NG.82
CONCLUSIONS
In conclusion, although dual therapy remains highly effec-
tive, existing isolates of infections with dual reduced susceptibility
to extended-spectrum cephalosporins and AZI threaten the current
recommended treatment for gonorrhea. Thus, new antimicrobials
and innovative prevention and control strategies are urgently
needed. Approaches to reduce AMR NG include the ongoing de-
velopment and careful introduction and stewardship of novel anti-
biotics, expanded AMR monitoring and better use of genomics
combined with companion diagnostics to rapidly identify infec-
tion and specific antimicrobial susceptibility, novel vaccine ap-
proaches, and special incentives for commercial diagnostic and
therapeutic developers.
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